Form 8-K

8-K — LifeStance Health Group, Inc.

Accession: 0001193125-26-336057

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001845257

SIC: 8000 (SERVICES-HEALTH SERVICES)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — lfst-20260806.htm (Primary)

EX-99.1 (lfst-ex99_1.htm)

EX-99.2 (lfst-ex99_2.htm)

GRAPHIC (lfst-ex99_2s1.jpg)

GRAPHIC (lfst-ex99_2s2.jpg)

GRAPHIC (lfst-ex99_2s3.jpg)

GRAPHIC (lfst-ex99_2s4.jpg)

GRAPHIC (lfst-ex99_2s5.jpg)

GRAPHIC (lfst-ex99_2s6.jpg)

GRAPHIC (lfst-ex99_2s7.jpg)

GRAPHIC (lfst-ex99_2s8.jpg)

GRAPHIC (lfst-ex99_2s9.jpg)

GRAPHIC (lfst-ex99_2s10.jpg)

GRAPHIC (lfst-ex99_2s11.jpg)

GRAPHIC (lfst-ex99_2s12.jpg)

GRAPHIC (lfst-ex99_2s13.jpg)

GRAPHIC (lfst-ex99_2s14.jpg)

GRAPHIC (lfst-ex99_2s15.jpg)

GRAPHIC (lfst-ex99_2s16.jpg)

GRAPHIC (lfst-ex99_2s17.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lfst-20260806.htm · Sequence: 1

8-K

0001845257false00018452572026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 06, 2026

LifeStance Health Group, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-40478

86-1832801

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

4800 N. Scottsdale Road

Suite 2500

Scottsdale, Arizona

85251

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 602 767-2100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

LFST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, LifeStance Health Group, Inc. ("LifeStance Health Group", "LifeStance" or the "Company") issued a press release announcing its results of operations for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1.

The information furnished under Item 2.02 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

A slide presentation, which includes supplemental information related to LifeStance Health Group, is furnished as Exhibit 99.2. The information furnished under Item 7.01 of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On August 5, 2026, the Board of Directors of the Company approved a share repurchase program, which authorizes the Company to repurchase up to $100 million of the Company's outstanding shares of common stock (the "Repurchase Program"). The Repurchase Program replaces the Company's prior $100 million repurchase program approved by the Board of Directors of the Company on February 24, 2026. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock. Stock repurchases under this program may be made at such times, prices, amounts and on such terms as the Company may determine from time to time to be advisable based on a variety of factors such as the market price of the Company's common stock, the Company's corporate requirements, other investment opportunities, and the overall market condition, with such repurchases effectuated in the open market or through privately negotiated transactions (including accelerated share repurchase programs), block purchases, or exchange or non-exchange transactions, and using such broker-dealer or broker-dealers as the Company may determine.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Description

99.1

Press Release dated August 6, 2026.

99.2

Slide presentation providing supplemental information.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LifeStance Health Group, Inc.

Date:

August 6, 2026

By:

/s/ Ryan McGroarty

Ryan McGroarty

Chief Financial Officer and Treasurer

(principal financial and accounting officer)

EX-99.1

Filename: lfst-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Investor Relations Contact

Monica Prokocki

VP of Finance & Investor Relations

602-767-2100

investor.relations@lifestance.com

LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook

Announces $100 Million Share Repurchase Program

SCOTTSDALE, Ariz. – August 6, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

Q2 2026 Highlights and FY 2026 Outlook

•

Revenue of $435.4 million increased 26% compared to revenue of $345.3 million

•

Clinician base increased 11% to 8,542 clinicians, a sequential net increase of 193 in the second quarter

•

Second quarter visit volumes increased 19% to 2.6 million

•

Net income of $23.6 million compared to net loss of $3.8 million

•

Adjusted EBITDA of $66.0 million compared to Adjusted EBITDA of $34.0 million

•

Net cash provided by operations of $99.9 million in the second quarter

•

Free Cash Flow generation of $87.9 million in the second quarter

•

For full year 2026, raising revenue expectations to $1.685 billion to $1.725 billion, Center Margin expectations to $570 million to $594 million, and Adjusted EBITDA of $215 million to $235 million

“This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.” said Dave Bourdon, CEO of LifeStance. “This momentum underscores the substantial growth opportunity ahead as we extend our reach into new geographies, broaden our specialty capabilities, and strengthen our differentiation through clinical excellence and measurable patient outcomes.”

Financial Highlights

Q2 2026

Q2 2025

Y/Y

(in millions)

Total revenue

435.4

345.3

Income (loss) from operations

30.7

(3.0

)

Center Margin

153.0

108.4

Net income (loss)

23.6

(3.8

)

Adjusted EBITDA

66.0

34.0

As % of Total revenue:

Income (loss) from operations

7.0

(0.9

Center Margin

35.2

31.4

Net income (loss)

5.4

(1.1

Adjusted EBITDA

15.2

9.8

NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

•

Revenue grew 26% to $435.4 million. Revenue growth in the second quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

•

income from operations was $30.7 million and net income was $23.6 million.

•

Center Margin grew 41% to $153.0 million, or 35.2% of total revenue.

•

Adjusted EBITDA increased 94% to $66.0 million, or 15.2% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the second quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the six months ended June 30, 2026, LifeStance generated $133.0 million of cash flow from operations, including $99.9 million during the second quarter of 2026. The Company ended the second quarter with cash and cash equivalents of $225.9 million and net long-term debt of $259.0 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

•

The Company is raising full year revenue to $1.685 billion to $1.725 billion, Center Margin to $570 million to $594 million, and Adjusted EBITDA to $215 million to $235 million.

•

For the third quarter of 2026, the Company expects total revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and Adjusted EBITDA of $49 million to $59 million.

Share Repurchase Program

The Company's Board of Directors has approved a share repurchase program authorizing the repurchase of up to $100 million of the Company's outstanding common stock, which replaces the Company's prior $100 million repurchase program approved by the Board of Directors of the Company on February 24, 2026. Repurchases may be made from time to time at the Company's discretion in the open market or through privately negotiated transactions, including accelerated share repurchase programs, subject to market conditions and other relevant factors.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, August 6, 2026 at 8:30 a.m. Eastern Time to discuss the second quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 6776851 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,500 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and third quarter guidance and management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain

or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income (loss) or income (loss) from operations.

Center Margin and Adjusted EBITDA anticipated for the third quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking third quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

# # # #

Consolidated Financial Information and Reconciliations

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except for par value)

June 30, 2026

December 31, 2025

CURRENT ASSETS

Cash and cash equivalents

225,943

248,642

Patient accounts receivable, net

110,960

95,710

Prepaid expenses and other current assets

41,063

71,848

Total current assets

377,966

416,200

NONCURRENT ASSETS

Property and equipment, net

164,696

161,583

Right-of-use assets

157,007

149,720

Intangible assets, net

172,805

177,665

Goodwill

1,304,556

1,293,346

Other noncurrent assets

4,466

5,419

Total noncurrent assets

1,803,530

1,787,733

Total assets

2,181,496

2,203,933

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable

11,053

6,122

Accrued payroll expenses

149,320

143,327

Other accrued expenses

49,551

42,187

Operating lease liabilities, current

46,500

45,544

Other current liabilities

18,329

14,782

Total current liabilities

274,753

251,962

NONCURRENT LIABILITIES

Long-term debt, net

258,991

265,927

Operating lease liabilities, noncurrent

154,159

148,553

Deferred tax liability, net

16,408

Other noncurrent liabilities

Total noncurrent liabilities

429,595

430,956

Total liabilities

704,348

682,918

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY

Preferred stock – par value $0.01 per share; 25,000 shares authorized as of

June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as

of June 30, 2026 and December 31, 2025

—

Common stock – par value $0.01 per share; 800,000 shares authorized as of

June 30, 2026 and December 31, 2025; 382,022 and 388,318 shares

issued and outstanding as of June 30, 2026 and December 31, 2025,

respectively

3,820

3,883

Additional paid-in capital

2,244,099

2,325,758

Accumulated deficit

(770,771

)

(808,626

)

Total stockholders' equity

1,477,148

1,521,015

Total liabilities and stockholders’ equity

2,181,496

2,203,933

consolidated statements of operations and comprehensive income (loss)

(unaudited)

(In thousands, except per share amounts)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

TOTAL REVENUE

435,354

345,311

838,830

678,281

OPERATING EXPENSES

Center costs, excluding depreciation and

amortization shown separately below

282,313

236,880

549,857

460,059

General and administrative expenses

108,139

97,375

208,469

191,806

Depreciation and amortization

14,249

14,006

27,567

27,762

Total operating expenses

404,701

348,261

785,893

679,627

INCOME (LOSS) FROM OPERATIONS

30,653

(2,950

)

52,937

(1,346

)

OTHER EXPENSE

Loss on remeasurement of contingent

consideration

(26

)

—

(31

)

—

Transaction costs

(445

)

—

(989

)

—

Interest expense, net

(2,632

)

(2,900

)

(4,425

)

(5,973

)

Other expense

(93

)

(92

)

(275

)

(93

)

Total other expense

(3,196

)

(2,992

)

(5,720

)

(6,066

)

INCOME (LOSS) BEFORE INCOME TAXES

27,457

(5,942

)

47,217

(7,412

)

INCOME TAX (PROVISION) BENEFIT

(3,845

)

2,151

(9,362

)

4,330

NET INCOME (LOSS)

23,612

(3,791

)

37,855

(3,082

)

EARNINGS (LOSS) PER SHARE

Basic

0.06

(0.01

)

0.10

(0.01

)

Diluted

0.06

(0.01

)

0.10

(0.01

)

Weighted-average shares outstanding

Basic

383,516

386,733

385,379

385,015

Diluted

387,299

386,733

391,181

385,015

NET INCOME (LOSS)

23,612

(3,791

)

37,855

(3,082

)

OTHER COMPREHENSIVE LOSS

Unrealized losses on cash flow hedge, net of tax

—

(267

)

—

(584

)

COMPREHENSIVE INCOME (LOSS)

23,612

(4,058

)

37,855

(3,666

)

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

Six Months Ended June 30,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES

Net income (loss)

37,855

(3,082

)

Adjustments to reconcile net income (loss) to net cash provided by operating

activities:

Depreciation and amortization

27,567

27,762

Non-cash operating lease costs

21,663

20,669

Stock-based compensation

34,949

39,700

Amortization of discount and debt issue costs

504

506

Other, net

1,283

753

Change in operating assets and liabilities, net of businesses acquired:

Patient accounts receivable, net

(14,402

)

2,318

Prepaid expenses and other current assets

30,810

(15,179

)

Accounts payable

3,946

(277

)

Accrued payroll expenses

5,430

11,725

Operating lease liabilities

(22,536

)

(23,498

)

Other accrued expenses

5,952

(93

)

Net cash provided by operating activities

133,021

61,304

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment

(22,761

)

(14,923

)

Acquisitions of businesses, net of cash acquired

(9,038

)

—

Net cash used in investing activities

(31,799

)

(14,923

)

CASH FLOWS FROM FINANCING ACTIVITIES

Payments of long-term debt

(7,250

)

(3,625

)

Taxes related to net share settlement of equity awards

(24,414

)

(8,398

)

Proceeds from the exercise of stock options

5,368

—

Repurchases of common stock

(97,625

)

—

Net cash used in financing activities

(123,921

)

(12,023

)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

(22,699

)

34,358

Cash and cash equivalents - beginning of period

248,642

154,571

CASH AND CASH EQUIVALENTS – END OF PERIOD

225,943

188,929

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid for interest, net

8,185

8,753

Cash paid for taxes, net of refunds

1,041

1,459

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND

FINANCING ACTIVITIES

Contingent consideration incurred in acquisitions of businesses

3,646

—

Acquisition of property and equipment included in liabilities

5,142

2,286

RECONCILIATION OF income (loss) FROM OPERATIONS TO CENTER MARGIN

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(in thousands)

Income (loss) from operations

30,653

(2,950

)

52,937

(1,346

)

Adjusted for:

Depreciation and amortization

14,249

14,006

27,567

27,762

General and administrative expenses (1)

108,139

97,375

208,469

191,806

Center Margin

153,041

108,431

288,973

218,222

(1)

Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.

RECONCILIATION OF NET income (loss) TO ADJUSTED EBITDA

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

(in thousands)

Net income (loss)

23,612

(3,791

)

37,855

(3,082

)

Adjusted for:

Interest expense, net

2,632

2,900

4,425

5,973

Depreciation and amortization

14,249

14,006

27,567

27,762

Income tax provision (benefit)

3,845

(2,151

)

9,362

(4,330

)

Loss on remeasurement of contingent

consideration

—

Stock-based compensation expense

19,748

21,116

34,949

39,700

Loss on disposal of assets

275

Transaction costs (1)

445

—

989

—

Executive transition costs

—

534

—

719

Litigation costs (2)

953

(128

)

1,158

Strategic initiatives (3)

911

—

997

—

Real estate optimization and restructuring

charges (4)

(11

)

(52

)

(11

)

(97

)

Amortization of cloud-based software

implementation costs (5)

423

398

841

755

Adjusted EBITDA

66,042

34,005

117,152

68,651

(1)

Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offerings of shares of our common stock by certain selling stockholders completed in the first and second quarters of 2026.

(2)

Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three and six months ended June 30, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three and six months ended June 30, 2025, a compensation model class action litigation.

(3)

Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses.

(4)

Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three and six months ended June 30, 2026 and 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023.

(5)

Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income (loss).

EX-99.2

Filename: lfst-ex99_2.htm · Sequence: 3

ReimaginingMental Health Q2 2026 Earnings Presentation • August 6, 2026 Exhibit 99.2

Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries (“LifeStance”) and the industry in which LifeStance operates, including statements regarding: full-year and third quarter guidance and management’s related assumptions; the Company's financial position; business plans and objectives; our share repurchase authorization and repurchases thereunder; including planned capital allocation; and potential for disciplined acquisitions; operating results; working capital and liquidity; and other statements contained in this presentation that are not historical facts. These statements are subject to known and unknown uncertainties and contingencies outside of LifeStance's control and which are largely based on our current expectations and projections about future events and financial trends that we believe may affect LifeStance's financial condition, results of operations, business strategy, and prospects. LifeStance's actual results, events, or circumstances may differ materially from these statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions, including, among other things: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors' security measures fail or are breached and unauthorized access to our employees', patients' or partners' data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and the other factors set forth in our filings with the Securities and Exchange Commission. The forward-looking statements, together with statements relating to our past performance, should not be regarded as a reliable indicator of our future performance. We undertake no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as may be required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future mergers, dispositions, joint ventures, or investments. Use of Non-GAAP Financial Measures In addition to financial measures presented in accordance with U.S. generally accepted accounting principles (“GAAP”), this presentation includes certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA Margin. These non-GAAP measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. The non-GAAP financial measures used by LifeStance may differ from the non-GAAP financial measures used by other companies. A reconciliation of these measures to the most directly comparable U.S. GAAP measure is included in the Appendix to these slides or as otherwise described in these slides. Market and Industry Data This presentation also contains information regarding our market and industry that is derived from third-party research and publications. This information involves a number of assumptions and limitations. Forecasts, assumptions, expectations, beliefs, estimates and projections involve risk and uncertainties and are subject to change based on various factors.

Building the Leading Outpatient Mental Health Platform Increasing access to trusted, affordable, and personalized mental healthcare A truly healthy society where mental and physical healthcare are unified to make lives better OUR VISION OUR MISSION Tech-enabled platform supporting hybrid model of virtual and in-person care In-network reimbursement providing affordable access to high-quality care National platform with unmatched scale Multidisciplinary clinician model composed of W-2 employed psychiatrists, APNs, psychologists & therapists 8,542Clinicians 11% Y/Y Growth $1,585M Revenue | TTM(1) 20% Y/Y TTM(1) Growth 9.8M Visits | TTM(1) 550+ Centers in 33 States 1 2 3 4 Note: Unless otherwise stated, data is as of June 30, 2026; (1) Trailing twelve months LifeStance: Reimagining Mental Healthcare

Q2 2026 Highlights Q2 Revenue of $435.4 million increased 26% year-over-year Total clinicians of 8,542 increased +11% Y/Y; 193 net clinician adds in Q2 Q2 visit volumes of 2.6 million increased +19% Y/Y Q2 Center Margin of $153.0 million, or 35.2% as a percentage of revenue Q2 Adjusted EBITDA of $66.0 million, or 15.2% as a percentage of revenue Ended Q2 with a Cash position of $225.9 million Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation. Amounts are unaudited.

Clinicians Q2 2026 Results Adjusted EBITDA (in $M) Center Margin (in $M) Revenue (in $M) 9.8% 15.2% 31.4% 35.2% Center Margin (% of total revenue) +41% +26% +11% +94% Adj. EBITDA (% of total revenue) Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation. Amounts are unaudited.

Quarterly Trends Clinicians Adjusted EBITDA (in $M) Adj. EBITDA (% of total revenue) Center Margin (in $M) Revenue (in $M) Center Margin (% of total revenue) 31.4% 32.0% 33.0% 33.7% 35.2% 9.8% 11.1% 12.8% 12.7% 15.2% Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation. Amounts above may not cross-foot due to rounding. Amounts are unaudited.

Balance Sheet, Cash Flow, and Capital Allocation *Long-Term Debt is Net of Current Portion and Unamortized Discount and Debt Issue Costs Balance Sheet & Cash Flow Capital Allocation Evolving from purely growth mindset to balanced set of objectives that include operational excellence, profitable growth, and disciplined capital deployment $259M Net Long-term Debt* Cash & Cash Equivalents $226M $133M Operating Cash Flow (YTD) $23M Capital Expenditures (YTD) New Centers Selective deployment to enable clinician and market growth Opened 6 new centers in Q2 and 12 YTD Acquisitions Disciplined investments to drive growth Completed 1 tuck-in acquisition in Q2 and 3 YTD

2026 Guidance (All $ in M) FY 2026 Q3 2026 Revenue $1,685 – $1,725(Raised from $1,640 - $1,680) $420 – $440 Center Margin $570 – $594(Raised from $547 - $571) $140 – $152 Adj. EBITDA $215 – $235(Raised from $200 - $220) $49 – $59 Note: Center Margin and Adjusted EBITDA anticipated for third quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures in the Appendix to this presentation. Reconciliation for the forward-looking third quarter of 2026 and full year 2026 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results. Planning Assumptions Assumes 20 to 30 new center openings

Appendix

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Total revenue $435.4 $403.5 $382.2 $363.8 $345.3 $333.0 Operating expenses Center costs, excluding depreciation and amortization 282.3 267.5 255.9 247.2 236.9 223.2 General and administrative expenses 108.1 100.3 94.8 95.6 97.4 94.4 Depreciation and amortization 14.2 13.3 13.4 13.6 14.0 13.8 Income (loss) from operations $30.7 $22.3 $18.1 $7.4 ($3.0) $1.6 Other expense Loss on remeasurement of contingent consideration (0.0) (0.0) — — — — Transaction costs (0.4) (0.5) — — — — Interest expense, net (2.6) (1.8) (2.9) (2.8) (2.9) (3.1) Other expense (0.1) (0.2) (0.0) (0.0) (0.1) (0.0) Total other expense (3.2) (2.5) (2.9) (2.8) (3.0) (3.1) Income (loss) before income taxes $27.5 $19.8 $15.2 $4.6 ($5.9) ($1.5) Income tax (provision) benefit (3.8) (5.5) (3.5) (3.5) 2.2 2.2 Net income (loss) $23.6 $14.2 $11.7 $1.1 ($3.8) $0.7 Earnings (loss) per share Basic 0.06 0.04 0.03 0.00 (0.01) 0.00 Diluted 0.06 0.04 0.03 0.00 (0.01) 0.00 Weighted-average shares outstanding Basic 383.5 387.3 387.0 387.0 386.7 383.3 Diluted 387.3 395.1 396.0 388.9 386.7 390.7 Net income (loss) $23.6 $14.2 $11.7 $1.1 ($3.8) $0.7 Other comprehensive loss Unrealized losses on cash flow hedge, net of tax — — — (0.3) (0.3) (0.3) Comprehensive income (loss) $23.6 $14.2 $11.7 $0.7 ($4.1) $0.4 Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. Quarterly Statements of Operations and Comprehensive Income (Loss)

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Income (loss) from operations $30.7 $22.3 $18.1 $7.4 ($3.0) $1.6 Adjusted for: Depreciation and amortization 14.2 13.3 13.4 13.6 14.0 13.8 General and administrative expenses (1) 108.1 100.3 94.8 95.6 97.4 94.4 Center Margin $153.0 $135.9 $126.3 $116.6 $108.4 $109.8 Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. (1) Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees. Quarterly GAAP to Non-GAAP Reconciliations – Center Margin

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Net income (loss) $23.6 $14.2 $11.7 $1.1 ($3.8) $0.7 Adjusted for: Interest expense, net 2.6 1.8 2.9 2.8 2.9 3.1 Depreciation and amortization 14.2 13.3 13.4 13.6 14.0 13.8 Income tax provision (benefit) 3.8 5.5 3.5 3.5 (2.2) (2.2) Loss on remeasurement of contingent consideration 0.0 0.0 — — — — Stock-based compensation 19.7 15.2 16.7 18.3 21.1 18.6 Loss on disposal of assets 0.1 0.2 0.0 0.0 0.1 0.0 Transaction costs (1) 0.4 0.5 — — — — Executive transition costs — — 0.1 0.6 0.5 0.2 Litigation costs (2) 0.1 (0.2) 0.1 (0.1) 1.0 0.2 Strategic initiatives (3) 0.9 0.1 — — — — Real estate optimization and restructuring charges (4) (0.0) — (0.0) (0.0) (0.1) (0.0) Amortization of cloud-based software implementation costs (5) 0.4 0.4 0.4 0.4 0.4 0.4 Adjusted EBITDA $66.0 $51.1 $48.8 $40.2 $34.0 $34.6 Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. (1) - Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offering of shares of our common stock by certain selling stockholders completed in the first and second quarters of 2026. (2) - Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three and six months ended June 30, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three and six months ended June 30, 2025, a compensation model class action litigation. (3) - Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. (4) - Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three and six months ended June 30, 2026 and 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023. (5) - Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income (loss). Quarterly GAAP to Non-GAAP Reconciliations – Adjusted EBITDA

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Key Metrics Clinicians 8,542 8,349 8,040 7,996 7,708 7,535 Total Revenue $435.4 $403.5 $382.2 $363.8 $345.3 $333.0 Center costs, excluding depreciation and amortization 282.3 267.5 255.9 247.2 236.9 223.2 Center Margin (Non-GAAP) $153.0 $135.9 $126.3 $116.6 $108.4 $109.8 % Margin 35.2% 33.7% 33.0% 32.0% 31.4% 33.0% General and administrative expenses 108.1 100.3 94.8 95.6 97.4 94.4 Depreciation and amortization 14.2 13.3 13.4 13.6 14.0 13.8 Income (loss) from operations 30.7 22.3 18.1 7.4 (3.0) 1.6 Other expense Other expense (7.0) (8.0) (6.4) (6.3) (0.8) (0.9) Net income (loss) 23.6 14.2 11.7 1.1 (3.8) 0.7 Other comprehensive loss Unrealized losses on cash flow hedge, net of tax — — — (0.3) (0.3) (0.3) Comprehensive income (loss) $23.6 $14.2 $11.7 $0.7 ($4.1) $0.4 Adjusted EBITDA build Net income (loss) 23.6 14.2 11.7 1.1 (3.8) 0.7 Interest expense, net 2.6 1.8 2.9 2.8 2.9 3.1 Depreciation and amortization 14.2 13.3 13.4 13.6 14.0 13.8 Income tax provision (benefit) 3.8 5.5 3.5 3.5 (2.2) (2.2) Loss on remeasurement of contingent consideration 0.0 0.0 — — — — Stock-based compensation 19.7 15.2 16.7 18.3 21.1 18.6 Loss on disposal of assets 0.1 0.2 0.0 0.0 0.1 0.0 Transaction costs 0.4 0.5 — — — — Executive transition costs — — 0.1 0.6 0.5 0.2 Litigation costs 0.1 (0.2) 0.1 (0.1) 1.0 0.2 Strategic initiatives 0.9 0.1 — — — — Real estate optimization and restructuring charges (0.0) — (0.0) (0.0) (0.1) (0.0) Amortization of cloud-based software implementation costs 0.4 0.4 0.4 0.4 0.4 0.4 Adjusted EBITDA (Non-GAAP) $66.0 $51.1 $48.8 $40.2 $34.0 $34.6 % Margin 15.2% 12.7% 12.8% 11.1% 9.8% 10.4% Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. Non-GAAP Financial Metrics

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Current assets Cash and cash equivalents 225.9 194.8 248.6 203.9 188.9 134.3 Patient accounts receivable, net 111.0 122.9 95.7 121.1 129.5 140.4 Prepaid expenses and other current assets 41.1 38.2 71.8 35.4 40.4 29.9 Total current assets 378.0 355.9 416.2 360.4 358.8 304.6 Property and equipment, net 164.7 161.5 161.6 162.7 160.6 163.7 Right-of-use assets 157.0 151.5 149.7 145.7 143.2 148.1 Intangible assets, net 172.8 175.1 177.7 180.8 184.0 187.3 Goodwill 1,304.6 1,297.0 1,293.3 1,293.3 1,293.3 1,293.3 Other noncurrent assets 4.5 4.8 5.4 6.1 6.9 7.6 Total noncurrent assets 1,803.5 1,790.0 1,787.7 1,788.6 1,788.0 1,800.0 Total assets $2,181.5 $2,145.9 $2,203.9 $2,149.0 $2,146.8 $2,104.7 Accounts payable 11.1 4.3 6.1 12.2 7.8 7.4 Accrued payroll expenses 149.3 117.3 143.3 113.8 129.2 99.9 Other accrued expenses 49.6 52.4 42.2 42.1 46.9 43.2 Operating lease liabilities, current 46.5 47.4 45.5 47.4 47.1 47.3 Other current liabilities 18.3 18.4 14.8 13.1 11.3 9.5 Total current liabilities 274.8 239.7 252.0 228.6 242.3 207.4 Long-term debt, net 259.0 262.5 265.9 269.4 272.9 276.3 Operating lease liabilities, noncurrent 154.2 148.8 148.6 144.2 143.4 149.4 Deferred tax liability, net 16.4 16.4 16.4 14.0 14.1 14.2 Other noncurrent liabilities 0.0 1.0 0.1 0.1 0.2 0.3 Total noncurrent liabilities 429.6 428.7 431.0 427.7 430.6 440.2 Total liabilities $704.3 $668.5 $682.9 $656.2 $672.9 $647.6 Common stock 3.8 3.9 3.9 3.9 3.9 3.9 Additional paid-in capital 2,244.1 2,267.9 2,325.8 2,309.1 2,291.1 2,270.2 Accumulated other comprehensive income — — — — 0.3 0.6 Accumulated deficit (770.8) (794.4) (808.6) (820.3) (821.4) (817.6) Total stockholders’ equity 1,477.1 1,477.4 1,521.0 1,492.7 1,473.9 1,457.1 Total liabilities and stockholders’ equity $2,181.5 $2,145.9 $2,203.9 $2,149.0 $2,146.8 $2,104.7 Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited. Quarterly Balance Sheets

($M) Six Months Ended Q2’26 Q1’26 Six Months Ended Q2’25 Q1’25 CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) $37.9 $14.2 ($3.1) $0.7 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 27.6 13.3 27.8 13.8 Non-cash operating lease costs 21.7 10.7 20.7 10.2 Stock-based compensation 34.9 15.2 39.7 18.6 Amortization of discount and debt issue costs 0.5 0.3 0.5 0.3 Other, net 1.3 0.1 0.8 0.4 Change in operating assets and liabilities, net of businesses acquired: Patient accounts receivable, net (14.4) (27.0) 2.3 (8.6) Prepaid expenses and other current assets 30.8 33.8 (15.2) (4.5) Accounts payable 3.9 (1.0) (0.3) (0.1) Accrued payroll expenses 5.4 (26.4) 11.7 (17.5) Operating lease liabilities (22.5) (10.0) (23.5) (11.9) Other accrued expenses 6.0 9.8 (0.1) (4.4) Net cash provided by (used in) operating activities $133.0 $33.1 $61.3 ($3.1) CASH FLOWS FROM INVESTING ACTIVITIES Purchases of property and equipment (22.8) (10.8) (14.9) (7.2) Acquisitions of businesses, net of cash acquired (9.0) (3.1) — — Net cash used in investing activities ($31.8) ($13.9) ($14.9) ($7.2) CASH FLOWS FROM FINANCING ACTIVITIES Payments of long-term debt (7.3) — (3.6) (1.8) Taxes related to net share settlement of equity awards (24.4) (23.9) (8.4) (8.2) Proceeds from the exercise of stock options 5.4 — — — Repurchases of common stock (97.6) (49.1) — — Net cash used in financing activities ($123.9) ($73.0) ($12.0) ($10.0) NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS ($22.7) ($53.8) $34.4 ($20.2) Cash and cash equivalents - beginning of period $248.6 $248.6 $154.6 $154.6 CASH AND CASH EQUIVALENTS – END OF PERIOD $225.9 $194.8 $188.9 $134.3 Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited. Statements of Cash Flows

2026 2025 ($M) Q2 Q1 Q4 Q3 Q2 Q1 Net cash provided by (used in) operating activities $99.9 $33.1 $57.6 $27.3 $64.4 ($3.1) Purchases of property and equipment ($12.0) ($10.8) ($10.9) ($10.3) ($7.8) ($7.2) Free Cash Flow $87.9 $22.3 $46.6 $17.0 $56.6 ($10.3) We define FCF, a non-GAAP performance measure, as net cash provided by (used in) operating activities less purchases of property and equipment. We believe that FCF is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. FCF is presented for supplemental informational purposes only and has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of other GAAP financial measures, such as net cash provided by (used in) operating activities. It is important to note that other companies, including companies in our industry, may not use this metric, may calculate metrics differently, or may use other financial measures to evaluate their liquidity, all of which could reduce the usefulness of this non-GAAP metrics as a comparative measure. The above table presents a reconciliation of net cash provided by (used in) operating activities to FCF, the most directly comparable financial measure calculated in accordance with GAAP. Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. Quarterly GAAP to Non-GAAP Reconciliations – Free Cash Flow (FCF)

2026 2025 Q2 Q1 Q4 Q3 Q2 Q1 Total Revenue ($M) $435.4 $403.5 $382.2 $363.8 $345.3 $333.0 Total Visits (000s) 2,613 2,468 2,394 2,299 2,199 2,098 Total Revenue Per Visit (TRPV) $166.6 $163.5 $159.6 $158.2 $157.0 $158.7 Subtotals in the schedule above may not foot or cross-foot due to rounding. Amounts are unaudited. Quarterly Visits and Total Revenue Per Visit

GRAPHIC

Filename: lfst-ex99_2s1.jpg · Sequence: 4

Binary file (132444 bytes)

Download lfst-ex99_2s1.jpg

GRAPHIC

Filename: lfst-ex99_2s2.jpg · Sequence: 5

Binary file (744902 bytes)

Download lfst-ex99_2s2.jpg

GRAPHIC

Filename: lfst-ex99_2s3.jpg · Sequence: 6

Binary file (353533 bytes)

Download lfst-ex99_2s3.jpg

GRAPHIC

Filename: lfst-ex99_2s4.jpg · Sequence: 7

Binary file (220278 bytes)

Download lfst-ex99_2s4.jpg

GRAPHIC

Filename: lfst-ex99_2s5.jpg · Sequence: 8

Binary file (206963 bytes)

Download lfst-ex99_2s5.jpg

GRAPHIC

Filename: lfst-ex99_2s6.jpg · Sequence: 9

Binary file (256372 bytes)

Download lfst-ex99_2s6.jpg

GRAPHIC

Filename: lfst-ex99_2s7.jpg · Sequence: 10

Binary file (328548 bytes)

Download lfst-ex99_2s7.jpg

GRAPHIC

Filename: lfst-ex99_2s8.jpg · Sequence: 11

Binary file (254191 bytes)

Download lfst-ex99_2s8.jpg

GRAPHIC

Filename: lfst-ex99_2s9.jpg · Sequence: 12

Binary file (98959 bytes)

Download lfst-ex99_2s9.jpg

GRAPHIC

Filename: lfst-ex99_2s10.jpg · Sequence: 13

Binary file (355035 bytes)

Download lfst-ex99_2s10.jpg

GRAPHIC

Filename: lfst-ex99_2s11.jpg · Sequence: 14

Binary file (236831 bytes)

Download lfst-ex99_2s11.jpg

GRAPHIC

Filename: lfst-ex99_2s12.jpg · Sequence: 15

Binary file (493261 bytes)

Download lfst-ex99_2s12.jpg

GRAPHIC

Filename: lfst-ex99_2s13.jpg · Sequence: 16

Binary file (335885 bytes)

Download lfst-ex99_2s13.jpg

GRAPHIC

Filename: lfst-ex99_2s14.jpg · Sequence: 17

Binary file (357650 bytes)

Download lfst-ex99_2s14.jpg

GRAPHIC

Filename: lfst-ex99_2s15.jpg · Sequence: 18

Binary file (331570 bytes)

Download lfst-ex99_2s15.jpg

GRAPHIC

Filename: lfst-ex99_2s16.jpg · Sequence: 19

Binary file (317140 bytes)

Download lfst-ex99_2s16.jpg

GRAPHIC

Filename: lfst-ex99_2s17.jpg · Sequence: 20

Binary file (177077 bytes)

Download lfst-ex99_2s17.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 23

v3.26.1

Document And Entity Information

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

LifeStance Health Group, Inc.

Entity Central Index Key

0001845257

Entity Emerging Growth Company

false

Entity File Number

001-40478

Entity Incorporation, State or Country Code

Entity Tax Identification Number

86-1832801

Entity Address, Address Line One

4800 N. Scottsdale Road

Entity Address, Address Line Two

Suite 2500

Entity Address, City or Town

Scottsdale

Entity Address, State or Province

Entity Address, Postal Zip Code

85251

City Area Code

602

Local Phone Number

767-2100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

LFST

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration